Clinical trials: Epithelial Neoplasms, Malignant
Non Small Cell Lung Cancer
Pharmacokinetic and Radiation Dosimetry Study Evaluating 99m TC-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
This is a multi-center Phase 1 b study designed to expand the patient safety using 99mTc-EC-DG with SPECT/CT imaging and to expand the patient radiation dosimetry and pharmacokinetic database using 99mTc-EC-DG in patients who…
- Trial name
- NCT00864110
- Testing
- Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose), Technetium 99m ethylenedicysteine-deoxyglucose, 18 F fluorodeoxyglucose
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Cell>Point LLC
Carcinoma, Hepatocellular
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of Serplulimab Injection (HLX10, a Recombinant Anti-PD-1 Antibody) and HLX04 (a Biosimilar to Bevacizumab) With…
- Trial name
- NCT06349980
- Testing
- HLX53 (1000mg), HLX53 (2000mg), HLX10
- Where
- China
- Volunteers
- 117 people
- Sponsor
- Shanghai Henlius Biotech
Basal Cell Carcinoma in Basal Cell Nevus Syndrome
Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)
The primary objective is to confirm the safety of treating multiple BCCs once weekly x 3 weeks in individuals with Basal Cell Nevus Syndrome (BCNS).
- Trial name
- NCT03208296
- Testing
- ASN-002
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ascend Biopharmaceuticals Ltd
Carcinoma, Hepatocellular
Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
The study will evaluate the efficacy and safety of sunitinib (Arm A), given at 37.5 mg orally once daily, compared to sorafenib (Arm B), given orally at 400 mg twice daily, in patients with inoperable liver cancer.
- Trial name
- NCT00699374
- Testing
- sunitinib malate, sorafenib
- Where
- 171 sites in United States, Australia and 21 more
- Volunteers
- 1,075 people
- Sponsor
- Pfizer
Non-small Cell Lung Cancer (NSCLC)
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR…
- Trial name
- NCT06074588
- Testing
- Sacituzumab tirumotecan, Docetaxel, Pemetrexed
- Where
- 195 sites in United States, Australia and 23 more
- Volunteers
- 556 people
- Sponsor
- Merck Sharp & Dohme LLC
Neuroblastoma, Pheochromocytoma
18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System
This is a prospective Phase 2 study being performed to document the relationship between 18F-mIBG positron emission tomography (PET) findings in subjects, and expression of the norepinephrine transporter.
- Conditions
- Neuroblastoma, Pheochromocytoma, Paraganglioma
- Trial name
- NCT06233903
- Testing
- 18F-mFBG
- Where
- United States
- Sponsor
- Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Non-Small Cell Lung Cancer
Clinical Evaluation of Genetron Lung Cancer Panel in Non-small Cell Lung Cancer Patients
The purpose of this trail is to evaluate the performance of Genetron lung cancer panel in non-small cell lung cancer patients using semiconductor sequencing method.
- Trial name
- NCT05023746
- Testing
- Genetron lung cancer panel
- Where
- 4 sites in China
- Volunteers
- 1,052 people
- Sponsor
- Genetron Health
Bladder Carcinoma in Situ (CIS)
Study of ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)
Phase I exploratory, open-label, single arm, multicenter study to assess safety, tolerability and antitumor activity of ONCOFID-P-B™ therapy in adult patients with histologically confirmed diagnosis of bladder carcinoma in situ…
- Trial name
- NCT04798703
- Testing
- ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)
- Where
- 5 sites in Italy, Spain
- Volunteers
- 20 people
- Sponsor
- Fidia Farmaceutici s.p.a.
Non Small-cell Lung Cancer, Locally Advanced Unresectable NSCLC
Expanded Access of Sotorasib
The primary objective of this study is to provide expanded access to and characterize the safety profile of Sotorasib in participants with previously treated locally advanced/unresectable/metastatic non small-cell lung cancer…
- Conditions
- Non Small-cell Lung Cancer, Locally Advanced Unresectable NSCLC, Locally Advanced Metastatic NSCLC
- Trial name
- NCT04667234
- Testing
- AMG 510
- Where
- 55 sites in United States, Argentina and 4 more
- Sponsor
- Amgen
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug[s]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab.
- Trial name
- NCT03972657
- Testing
- REGN5678, Cemiplimab
- Where
- 27 sites in United States, South Korea
- Volunteers
- 345 people
- Sponsor
- Regeneron Pharmaceuticals
Glioblastoma Multiforme
A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme
To evaluate CAN008 safety, tolerability, and pharmacokinetics (PK) of CAN008 when administered concurrent Plus Concomitant Temozolomide During and After Radiation Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme.
- Trial name
- NCT02853565
- Testing
- CAN008
- Where
- 2 sites in Taiwan
- Volunteers
- 10 people
- Sponsor
- CANbridge Life Sciences Ltd.
Neoplastic Disease, Glioblastoma
131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)
This is an open label, single arm, parallel-group, multicentre, and dose finding study to evaluate the safety of ascending radioactive dose levels of 131I-TLX101 administered intravenously in combination with best standard of…
- Conditions
- Neoplastic Disease, Glioblastoma, Glioblastoma Multiforme
- Trial name
- IPAX-2 (NCT05450744)
- Testing
- 131I-IPA
- Where
- 5 sites in Australia, Austria and 1 more
- Volunteers
- 12 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
- Trial name
- DeLLphi-312 (NCT07005128)
- Testing
- Tarlatamab, Durvalumab, Carboplatin
- Where
- 164 sites in United States, Argentina and 24 more
- Volunteers
- 350 people
- Sponsor
- Amgen
Hepatocellular Carcinoma (HCC)
A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
This is a Phase 2, Open-label, Randomized, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Brivanib in Patients with Previously Treated Advanced Hepatocellular Carcinoma.
- Trial name
- NCT03516071
- Testing
- Brivanib 800 mg, QD, Brivanib 400 mg, BID
- Where
- 15 sites in China
- Volunteers
- 90 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Metastatic Renal Cell Carcinoma
Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients
The primary purpose is to monitor the safety and tolerability and effectiveness of sunitinib malate in the treatment of patients with metastatic renal cell carcinoma and gastrointestinal stromal tumor among filipino patients in…
- Trial name
- NCT01073644
- Testing
- Sunitinib malate
- Where
- 2 sites in Philippines
- Volunteers
- 3 people
- Sponsor
- Pfizer
Small Cell Lung Cancer
Trial of BMS-986012 in Combination With Platinum and Etoposide
The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.
- Trial name
- NCT02815592
- Testing
- BMS-986012, Cisplatin, Etoposide
- Where
- 4 sites in Spain
- Volunteers
- 12 people
- Sponsor
- Bristol-Myers Squibb
Advanced Cancer
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families.
- Trial name
- NCT02219711
- Testing
- MGCD516
- Where
- 43 sites in United States, South Korea
- Volunteers
- 193 people
- Sponsor
- Mirati Therapeutics Inc.
Carcinoma, Solid Tumor, Adult
A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours
To investigate safety, tolerability and pharmacokinetics of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours that are not eligible for conventional or intensive treatment.
- Trial name
- NCT02977364
- Testing
- HS-10241
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Advanced Neoplasms
Study of E7386 in Participants With Selected Advanced Neoplasms
This study will be conducted to assess the safety/tolerability profile of E7386 as a single agent administered orally in participants with selected advanced or recurrent neoplasms and to determine the maximum tolerated dose (MTD)…
- Trial name
- NCT03264664
- Testing
- E7386
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Eisai Inc.
Solid Tumors
Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors
The purpose of this study was to assess the safety of the combination of relacorilant (CORT125134), a novel glucocorticoid receptor (GR) antagonist, and nab- paclitaxel in participants with solid tumors and to determine the…
- Trial name
- NCT02762981
- Testing
- Relacorilant with nab-paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 85 people
- Sponsor
- Corcept Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.